ADITXT INC (ADTX)       1.515  +0.07 (+5.21%)

1.515  +0.07 (+5.21%)

US0070255056 - Common Stock - After market: 1.55 +0.04 (+2.31%)

ADITXT INC1.515

NASDAQ:ADTX (2/3/2023, 7:23:33 PM)+0.07 (+5.21%)

After market: 1.55 +0.04 (+2.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) N/A N/A
Ins Owners 0% Inst Owners 0.07%
Market Cap 6.51M Shares 4.30M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 06-19 2020-06-19

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADTX Daily chart

Company Profile

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The company is headquartered in Richmond, Virginia and currently employs 58 full-time employees. The company went IPO on 2020-06-19. The firm is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.

Company Info

ADITXT INC

737 N. Fifth Street, Suite 200

Richmond VIRGINIA 94043

P: 19094880844.0

CEO: Amro Albanna

Employees: 58

Website: https://aditxt.com/